Related content

Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel

By Tung Nadine   Battelli Chiara   Allen Brian   Kaldate Rajesh   Bhatnagar Satish   Bowles Karla   Timms Kirsten   Garber Judy E.   Herold Christina   Ellisen Leif   Krejdovsky Jill   DeLeonardis Kim   Sedgwick Kristin   Soltis Kathleen   Roa Benjamin   Wenstrup Richard J.   Hartman Anne-Renee  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 25-33

Blackwell Publishing

Access to resources Recommend Favorite

Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian

By Mersch Jacqueline   Jackson Michelle A.   Park Minjeong   Nebgen Denise   Peterson Susan K.   Singletary Claire   Arun Banu K.   Litton Jennifer K.  

Cancer, Vol. 121, Iss. 2, 2015-01 ,pp. : 269-75

Blackwell Publishing

Access to resources Recommend Favorite

Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer

By Liu Guoyan   Yang Da   Sun Yan   Shmulevich Ilya   Xue Fengxia   Sood Anil K   Zhang Wei  

Pharmacogenomics, Vol. 13, Iss. 13, 2012-10 ,pp. : 1523-1535

Future Medicine

Access to resources Recommend Favorite

Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?

By  

Current Pharmacogenomics, Vol. 5, Iss. 4, 2007-12 ,pp. : 280-291

Bentham Science Publishers

Access to resources Recommend Favorite

BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer

By Sakamoto Ikuko   Hirotsu Yosuke   Nakagomi Hiroshi   Ouchi Hidetaka   Ikegami Atsushi   Teramoto Katsuhiro   Amemiya Kenji   Mochizuki Hitoshi   Omata Masao  

Cancer, Vol. 122, Iss. 1, 2016-01 ,pp. : 84-90

Blackwell Publishing

Access to resources Recommend Favorite